Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical combination of **dehydroepiandrosterone (DHEA)**, a steroid hormone and precursor of sex hormones, and **triiodothyroacetic acid (TRIAC)**, a thyroid hormone analog, that is designed to **stimulate collagen synthesis and treat corticosteroid-induced and other forms of skin atrophy**. The combination has demonstrated a **synergistic effect** in preclinical and early pharmacokinetic studies, stimulating type I procollagen synthesis in human skin more effectively than either agent alone. This combination is intended primarily for **topical administration** to the skin, offering a potential treatment for dermatological conditions such as atrophoderma resulting from corticosteroid use, photoaging, or aging. The mechanism is thought to involve hormone receptor-mediated signaling pathways in skin fibroblasts to enhance extracellular matrix production[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dehydroepiandrosterone + triiodothyroacetic acid.